New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
Acute myeloid leukemia continues to present formidable treatment challenges as there is not yet a "standard approach" that reliably and safely cures the majority of adults with this disorder. Efforts to better understand the basic cellular and molecular biology of acute myeloid leukemia have unveiled a complicated network of signaling pathways that support the cancer cells. Disrupting the transmission of the cells' survival signals offers appealing targets for drug development. This review will focus on several exciting components of these pathways and the agents targeting these pathways that are entering clinical trials.
Bao
Ting
T
Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Smith
B Douglas
BD
Karp
Judith E
JE
D000208:Acute Disease; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D005544:Forecasting; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D047908:Intracellular Signaling Peptides and Proteins; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051231:Farnesyltranstransferase; D011494:Protein Kinases; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3